Newron's Evenamide Takes Center Stage at Key Schizophrenia Conference

Newron presents Evenamide data at SIRS 2026, with pivotal Phase III readouts expected Q4 2026. The firm reported a €13.2M net loss for 2025 but strengthened cash to €28.9M.

Italian pharmaceutical firm Newron SpA is in the spotlight at a major global schizophrenia congress in Florence, presenting fresh data on its lead candidate, Evenamide. With pivotal Phase III trials advancing at full speed, investor attention is firmly fixed on the final quarter of 2026, when the first efficacy readouts—critical for the compound's future—are anticipated.

Financial Backing and Market Performance

The company's financial position reflects its intensive clinical development efforts. For the full year 2025, Newron reported a net loss of €13.2 million. This contrasts with a profit of €15.8 million in the prior year, a result attributed to a one-time upfront payment from partner EA Pharma. More crucial for funding the ongoing trial program is the company's liquidity, which was strengthened through capital measures. Cash and equivalents rose to €28.9 million by the end of 2025.

On the market, Newron's shares have faced pressure since the start of the year, declining by over 38% since January. The stock currently trades at €16.46, managing to hold just above its 200-day moving average.

Clinical Program and Mechanism of Action

At the ongoing SIRS Congress 2026, Newron is detailing the specific mechanism of its oral drug. Evenamide selectively blocks voltage-gated sodium channels, differentiating it from existing antipsychotic treatments. The company is currently recruiting patients worldwide for two major Phase III studies, ENIGMA-TRS 1 and 2. These trials are evaluating the efficacy and safety of the drug as an adjunctive therapy for treatment-resistant schizophrenia. Management expects initial results for the primary endpoint after twelve weeks in the fourth quarter of 2026.

Upcoming Corporate Calendar

The next formal milestones for the business are already scheduled. Shareholders will convene for the Annual General Meeting at the company's headquarters in Bresso, Italy, on April 23, 2026. The agenda includes the approval of the 2025 financial statements and the regular election of board members for the upcoming three-year term.